Evidence for HIV-1 cure after CCR5Δ32/Δ32 allogeneic haemopoietic stem-cell transplantation 30 months post analytical treatment interruption: a case report

被引:148
|
作者
Gupta, Ravindra Kumar [1 ,2 ]
Peppa, Dimitra [3 ,11 ]
Hill, Alison L. [4 ]
Galvez, Cristina [5 ,6 ]
Salgado, Maria [5 ]
Pace, Matthew [3 ]
McCoy, Laura E. [7 ]
Griffith, Sarah A. [7 ]
Thornhill, John [8 ]
Alrubayyi, Aljawharah [3 ]
Huyveneers, Laura E. P. [9 ]
Nastouli, Eleni [7 ,10 ,11 ]
Grant, Paul [10 ]
Edwards, Simon G. [12 ]
Innes, Andrew J. [8 ,13 ]
Frater, John [3 ,14 ]
Nijhuis, Monique [9 ]
Wensing, Anne Marie J. [9 ]
Martinez-Picado, Javier [5 ,15 ,16 ]
Olavarria, Eduardo [8 ,12 ]
机构
[1] Univ Cambridge, Dept Med, Cambridge CB2 0QQ, England
[2] Africa Hlth Res Inst, Durban, South Africa
[3] Univ Oxford, Nuffield Dept Med, Oxford, England
[4] Harvard Univ, Dept Organism & Evolutionary Biol, Cambridge, MA 02138 USA
[5] IrsiCaixa Aids Res Inst, Badalona, Spain
[6] Autonomous Univ Barcelona, Cerdanyola Del Valles, Spain
[7] Univ Coll London UCL, Div Infect & Immun, London, England
[8] Imperial Coll London, London, England
[9] Univ Med Ctr, Dept Med Microbiol, Utrecht, Netherlands
[10] UCL Hosp, Dept Virol, London, England
[11] UCL Great Ormond St Inst Child Hlth, Populat Policy & Practice, London, England
[12] Cent & North West London NHS Trust, Dept HIV, Mortimer Market Ctr, London, England
[13] Hammersmith Hosp, Imperial Coll NHS Healthcare Trust, London, England
[14] Oxford Natl Inst Hlth, Res Biomed Res Ctr, Oxford, England
[15] Univ Vic, Cent Univ Catalonia, Vic, Spain
[16] Catalan Inst Res & Adv Studies, Barcelona, Spain
来源
LANCET HIV | 2020年 / 7卷 / 05期
基金
英国医学研究理事会; 英国惠康基金;
关键词
T-CELLS; INFECTION; CCR5; PATIENT; SAMHD1; BLOOD;
D O I
10.1016/S2352-3018(20)30069-2
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background The London patient (participant 36 in the IciStem cohort) underwent allogeneic stem-cell transplantation with cells that did not express CCR5 (CCR5 Delta 32/Delta 32); remission was reported at 18 months after analytical treatment interruption (ATI). Here, we present longer term data for this patient (up to 30 months after ATI), including sampling from diverse HIV-1 reservoir sites. Methods We used ultrasensitive viral load assays of plasma, semen, and cerebrospinal fluid (CSF) samples to detect HIV-1 RNA. In gut biopsy samples and lymph-node tissue, cell-copy number and total HIV-1 DNA levels were quantified in multiple replicates, using droplet digital PCR (ddPCR) and quantitative real-time PCR. We also analysed the presence of intact proviral DNA using multiplex ddPCR targeting the packaging signal (psi) and envelope (env). We did intracellular cytokine staining to measure HIV-1-specific T-cell responses. We used low-sensitive and low-avidity antibody assays to measure the humoral response to HIV-1. We predicted the probability of rebound using a mathematical model and inference approach. Findings HIV-1 viral load in plasma remained undetectable in the London patient up to 30 months (last tested on March 4, 2020), using an assay with a detection limit of 1 copy per mL. The patient's CD4 count was 430 cells per mu L (23.5% of total T cells) at 28 months. A very low-level positive signal for HIV-1 DNA was recorded in peripheral CD4 memory cells at 28 months. The viral load in semen was undetectable in both plasma (lower limit of detection [LLD] <12 copies per mL) and cells (LLD 10 copies per 10(6) cells) at 21 months. CSF was within normal parameters at 25 months, with HIV-1 RNA below the detection limit (LLD 1 copy per mL). HIV-1 DNA by ddPCR was negative in rectum, caecum, and sigmoid colon and terminal ileum tissue samples at 22 months. Lymph-node tissue from axilla was positive for the long-terminal repeat (33 copies per 10(6) cells) and env (26.1 copies per 106 cells), negative for psi and integrase, and negative by the intact proviral DNA assay, at 27 months. HIV-1-specific CD4 and CD8 T-cell responses have remained absent at 27 months. Low-avidity Env antibodies have continued to decline. Mathematical modelling suggests that the probability of remission for life (cure) is 98% in the context of 80% donor chimerism in total HIV target cells and greater than 99% probability of remission for life with 90% donor chimerism. Interpretation The London patient has been in HIV-1 remission for 30 months with no detectable replication-competent virus in blood, CSF, intestinal tissue, or lymphoid tissue. Donor chimerism has been maintained at 99% in peripheral T cells. We propose that these findings represent HIV-1 cure. Copyright (C) 2020 The Author(s). Published by Elsevier Ltd.
引用
收藏
页码:E340 / E347
页数:8
相关论文
共 30 条
  • [2] HIV-1 cure after CCR5Δ32/Δ32 allogeneic hematopoietic stem cell transplantation
    Jensen, Bjorn-Erik Ole
    Kobbe, Guido
    NATURE MEDICINE, 2023, 29 (3) : 547 - 548
  • [3] Evidence for the cure of HIV infection by CCR5Δ32/Δ32 stem cell transplantation
    Allers, Kristina
    Huetter, Gero
    Hofmann, Joerg
    Loddenkemper, Christoph
    Rieger, Kathrin
    Thiel, Eckhard
    Schneider, Thomas
    BLOOD, 2011, 117 (10) : 2791 - 2799
  • [4] HIV-1 remission following CCR5Δ32/Δ32 haematopoietic stem-cell transplantation
    Gupta, Ravindra K.
    Abdul-Jawad, Sultan
    Mccoy, Laura E.
    Mok, Hoi Ping
    Peppa, Dimitra
    Salgado, Maria
    Martinez-Picado, Javier
    Nijhuis, Monique
    Wensing, Annemarie M. J.
    Lee, Helen
    Grant, Paul
    Nastouli, Eleni
    Lambert, Jonathan
    Pace, Matthew
    Salasc, Fanny
    Monit, Christopher
    Innes, Andrew J.
    Muir, Luke
    Waters, Laura
    Frater, John
    Lever, Andrew M. L.
    Edwards, Simon G.
    Gabriel, Ian H.
    Olavarria, Eduardo
    NATURE, 2019, 568 (7751) : 244 - +
  • [5] HIV-1 remission following CCR5Δ32/Δ32 haematopoietic stem-cell transplantation
    Ravindra K. Gupta
    Sultan Abdul-Jawad
    Laura E. McCoy
    Hoi Ping Mok
    Dimitra Peppa
    Maria Salgado
    Javier Martinez-Picado
    Monique Nijhuis
    Annemarie M. J. Wensing
    Helen Lee
    Paul Grant
    Eleni Nastouli
    Jonathan Lambert
    Matthew Pace
    Fanny Salasc
    Christopher Monit
    Andrew J. Innes
    Luke Muir
    Laura Waters
    John Frater
    Andrew M. L. Lever
    Simon G. Edwards
    Ian H. Gabriel
    Eduardo Olavarria
    Nature, 2019, 568 : 244 - 248
  • [6] In-depth virological and immunological characterization of HIV-1 cure after CCR5Δ32/Δ32 allogeneic hematopoietic stem cell transplantation
    Jensen, Bjoern-Erik Ole
    Knops, Elena
    Cords, Leon
    Luebke, Nadine
    Salgado, Maria
    Busman-Sahay, Kathleen
    Estes, Jacob D. D.
    Huyveneers, Laura E. P.
    Perdomo-Celis, Federico
    Wittner, Melanie
    Galvez, Cristina
    Mummert, Christiane
    Passaes, Caroline
    Eberhard, Johanna M. M.
    Muenk, Carsten
    Hauber, Ilona
    Hauber, Joachim
    Heger, Eva
    De Clercq, Jozefien
    Vandekerckhove, Linos
    Bergmann, Silke
    Dunay, Gabor A.
    Klein, Florian
    Haeussinger, Dieter
    Fischer, Johannes C. C.
    Nachtkamp, Kathrin
    Timm, Joerg
    Kaiser, Rolf
    Harrer, Thomas
    Luedde, Tom
    Nijhuis, Monique
    Saez-Cirion, Asier
    Wiesch, Julian Schulze zur
    Wensing, Annemarie M. J.
    Martinez-Picado, Javier
    Kobbe, Guido
    NATURE MEDICINE, 2023, 29 (03) : 583 - +
  • [7] In-depth virological and immunological characterization of HIV-1 cure after CCR5Δ32/Δ32 allogeneic hematopoietic stem cell transplantation
    Björn-Erik Ole Jensen
    Elena Knops
    Leon Cords
    Nadine Lübke
    Maria Salgado
    Kathleen Busman-Sahay
    Jacob D. Estes
    Laura E. P. Huyveneers
    Federico Perdomo-Celis
    Melanie Wittner
    Cristina Gálvez
    Christiane Mummert
    Caroline Passaes
    Johanna M. Eberhard
    Carsten Münk
    Ilona Hauber
    Joachim Hauber
    Eva Heger
    Jozefien De Clercq
    Linos Vandekerckhove
    Silke Bergmann
    Gábor A. Dunay
    Florian Klein
    Dieter Häussinger
    Johannes C. Fischer
    Kathrin Nachtkamp
    Joerg Timm
    Rolf Kaiser
    Thomas Harrer
    Tom Luedde
    Monique Nijhuis
    Asier Sáez-Cirión
    Julian Schulze zur Wiesch
    Annemarie M. J. Wensing
    Javier Martinez-Picado
    Guido Kobbe
    Nature Medicine, 2023, 29 : 583 - 587
  • [8] HIV Cure Following CCR5 Δ32 Stem Cell Transplantation - An Update
    Benito, Jose M.
    AIDS REVIEWS, 2011, 13 (01) : 58 - 58
  • [9] Absence of viral rebound without antiretrovirals after CCR5Δ32/Δ32 allogeneic hematopoietic stem cell transplantation: a new case of a potential cure of HIV?
    Zaegel-Faucher, Olivia
    Boschi, Celine
    Benkouiten, Samir
    Laroche, Helene
    Dos Santos, Maeva
    Motte, Anne
    Izadifar-Legrand, Faezeh
    Olive, Daniel
    Colson, Philippe
    Bregigeon-Ronot, Sylvie
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2024, 27 : 194 - 195
  • [10] Treatment of HIV-1 infection by allogeneic CCR5-delta32 stem cell transplantation
    Huetter, G.
    Nowak, D.
    Mossner, M.
    Ganepola, S.
    Allers, K.
    Schneider, T.
    Hofmann, J.
    Hofmann, W. K.
    Thiel, E.
    BONE MARROW TRANSPLANTATION, 2008, 41 : S123 - S123